GGrantIndex
Sort

261,768 grants matching gene therapy

Cellular Interactions with Thrombospondin

$1,414,291
David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA

Genetic Susceptibility and Biomarkers of Platinum-related Toxicities

$1,414,272
Lois B. Travis · University Of Rochester · R01 · FY2013 · CA

Epigenetic mechanisms regulating the Igf2/H19 and Kcnq1 locus

$1,414,139
Karl Eric Pfeifer · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2013 · HD

Molecular Genetic Study of Stem Cells, Cancer Stem Cells, and Stem Cell Aging

$1,414,061
Xianyu S Hou · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Therapeutic Vaccination for HIV Using VEE Vectors

$1,413,970
University Of North Carolina Chapel Hill · P01 · FY2004 · AI

NHGRI/DIR Technology Transfer Program

$1,413,857
Claire Driscoll · National Human Genome Research Institute · ZIK · FY2020 · HG

Remodeling and recovery in the neurovascular unit

$1,413,847
Eng H. Lo · Massachusetts General Hospital · P01 · FY2015 · NS

Vascular remodeling in patients with rare genetic disorders

$1,413,751
Manfred Boehm · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL

MRI Studies of Brain Function and Metabolism

$1,413,684
Karen Faith Berman · National Institute Of Mental Health · ZIA · FY2013 · MH

Disease mechanism and therapies for retinal degeneration

$1,413,623
Tiansen Li · National Eye Institute · ZIA · FY2013 · EY

Genome-Wide Association Studies of Adiposity in Samoans

$1,413,321
Stephen T. McGarvey · Brown University · R01 · FY2009 · HL

Synthetic Cell State Engineering for Primary Human Cellular Therapies

$1,413,277
Theodore Lee Roth · Stanford University · DP2 · FY2025 · CA

Improving Mitral Compensation In Ischemic Regurgitation

$1,413,244
Robert A Levine · Massachusetts General Hospital · R01 · FY2018 · HL

The LUCINDA Trial

$1,413,113
Tracy A. Butler · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · AG

Muscular Dystrophy Cooperative Research Center

$1,412,829
Richard T Moxley · University Of Rochester · U54 · FY2012 · NS

Therapeutics targeting TDP-43 to treat Alzheimer's disease and related disorders

$1,412,771
Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · U01 · FY2021 · AG

Pathogenesis of Novel Forms of Osteogenesis Imperfecta

$1,412,624
Brendan Hl Lee · Baylor College Of Medicine · P01 · FY2019 · HD

Pathogenesis of Novel Forms of Osteogenesis Imperfecta

$1,412,624
Brendan Hl Lee · Baylor College Of Medicine · P01 · FY2017 · HD

Pathogenesis of Novel Forms of Osteogenesis Imperfecta

$1,412,624
Brendan Hl Lee · Baylor College Of Medicine · P01 · FY2018 · HD

Pathogenesis of Novel Forms of Osteogenesis Imperfecta

$1,412,624
Brendan Hl Lee · Baylor College Of Medicine · P01 · FY2020 · HD

Mechanisms of dopamine neuron degeneration

$1,412,585
Robert E Burke · Columbia University Health Sciences · P50 · FY2006 · NS

Gene Therapy for Brain Tumors

$1,412,570
Fred H Hochberg · Massachusetts General Hospital · P01 · FY2009 · CA

Mechanisms of dopamine neuron degeneration

$1,412,467
Robert E Burke · Columbia University Health Sciences · P50 · FY2007 · NS

Next generation T cell therapies for mutant KRAS solid tumors

$1,412,213
Beatriz M. Carreno · University Of Pennsylvania · UG3 · FY2024 · CA

Mechanisms of dopamine neuron degeneration

$1,412,203
Robert E Burke · Columbia University Health Sciences · P50 · FY2008 · NS